Syros Pharmaceuticals Inc. appointed Michael Bonney to its board of directors.

Bonney is CEO and board chair of biotechnology company Kaleido Biosciences and is also chairman of the boards of Alnylam Pharmaceuticals Inc. and Magenta Therapeutics Inc.

His previous roles include CEO of Cubist Pharmaceuticals LLC, now owned by Merck & Co. Inc., and vice president of sales and marketing at Biogen Inc.

In addition, Syros directors Robert Nelson and Sanj Patel stepped down from the board.

Cambridge, Mass.-based Syros Pharmaceuticals is a biopharmaceutical company focused on cancer and monogenic diseases.